A Phase II/III Study of JR-141 in Patients With Mucopolysaccharidosis II
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2019
Price : $35 *
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Therapeutic Use
- Sponsors JCR Pharmaceuticals
- 28 Dec 2018 Status changed from recruiting to active, no longer recruiting, according to a JCR Pharmaceuticals media release.
- 09 Aug 2018 Status changed from not yet recruiting to recruiting, according to a JCR Pharmaceuticals media release.
- 13 Jun 2018 Status changed from planning to not yet recruiting.